STP 1
Alternative Names: STALICLA Therapeutic Package 1; STP-1Latest Information Update: 28 Apr 2026
At a glance
- Originator STALICLA
- Class Behavioural disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Phosphoric diester hydrolase inhibitors; Sodium-potassium-chloride symporter inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autism spectrum disorder
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for phase-I development in Autism-spectrum-disorder in USA (PO, Capsule)
- 28 Apr 2026 No recent reports of development identified for phase-I development in Autism-spectrum-disorder in USA (PO, Tablet)
- 28 Apr 2026 No recent reports of development identified for preclinical development in Autism-spectrum-disorder in Switzerland